vimarsana.com
Home
Live Updates
NeoGenomics, Inc.: NeoGenomics to Leverage Thermo Fisher Sci
NeoGenomics, Inc.: NeoGenomics to Leverage Thermo Fisher Sci
NeoGenomics, Inc.: NeoGenomics to Leverage Thermo Fisher Scientific's Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers
FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced
Related Keywords
Fort Myers ,
Florida ,
United States ,
Georgia ,
Tampa ,
North Carolina ,
United Kingdom ,
Texas ,
Research Triangle Park ,
Atlanta ,
California ,
San Diego ,
Tennessee ,
Singapore ,
Houston ,
Aliso Viejo ,
Cambridge ,
Cambridgeshire ,
Switzerland ,
American ,
Garret Hampton ,
Charlie Eidson ,
Mark Mallon ,
Doug Brown ,
Neogenomics Inc ,
Thermo Fisher ,
Company Pharma Services Division ,
Nasdaq ,
While The Company ,
Company Annual Report On Form ,
Corporate Development ,
American Society Of Hematologists ,
Thermo Fisher Scientific ,
Ion Torrent Genexus System ,
Oncomine Myeloid Assay ,
American Society ,
Annual Meeting ,
Atlanta December ,
Genexus System ,
Target Test ,
Pharma Services Division ,
Privacy Practices ,
Private Securities Litigation Reform Act ,
Annual Report ,
Corporate Development Officer ,
Investor Relations ,
Neogenomics ,
Beverage ,
Thermo ,
Fisher ,
Cientific ,
Torrent ,
Genexus ,
System ,
Pcoming ,
Hase ,
Study ,
Amyeloid ,
Cancers ,